Project Grant R21AI202210
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $225,846 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antivirulence inhibitors targeting bacterial type IV pili as a strategy against antibiotic resistance. The project advances small-molecule therapeutics that interfere with type IV pilus biogenesis and function in gram-negative pathogens. Rather than killing bacteria...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $808,607 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize AI-designed antimicrobial peptides targeting ESKAPE pathogens. The project integrates artificial intelligence, machine learning, chemical approaches, and computational tools to develop peptide-based therapeutics against multidrug-resistant bacteria including...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $668,128 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop artificial intelligence and machine learning methods for hospital-acquired infection risk prediction, surveillance, and infection control. The recipient will design a multi-disciplinary approach combining deep learning, agent-based modeling, human factors, and systems science to address gaps...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $432,155 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a co-infection model examining how bacterial pathogens alter West Nile Virus transmission dynamics in songbirds. The research experimentally tests whether co-infection of wild-caught house finches—a key amplifying reservoir for West Nile Virus—with a common bacterial...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts $2,641,186 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antimicrobial poly(oxanorborneneimide) polymers (PONI-AMPs) for treating multidrug-resistant wound biofilm infections. The research integrates synthetic chemistry, atomistic computational modeling, and machine learning to evolve PONI-AMP therapeutics. Initial work demonstrated 99...
- The National Institute of Allergy and Infectious Diseases awarded Georgia TECH Research Corp $149,190 on January 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate R-pyocins as a therapeutic approach to treat high-risk, multidrug-resistant Pseudomonas aeruginosa wound infections. The project addresses the rising prevalence of multidrug-resistant and extensively drug-resistant P. aeruginosa strains that cause acute and chronic infections from...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $437,541 to Virginia Polytechnic Institute & State University on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antisense therapeutics targeting Clostridioides difficile infection. The research focuses on designing antisense oligomers, including peptide nucleic acids, to suppress...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $199,059 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study competitive microbial interactions driving pathogen adaptation during biofilm-associated infections. The research addresses polymicrobial chronic wound infections, which are predicted to affect 2 percent of the U.S. population and cost the healthcare system up to $97 billion annually. The project combines a porcine full-thickness thermal injury wound model with microbial single-cell lineage tracking and next-generation sequencing to analyze polymicrobial interactions in clinically relevant infection contexts. The work tests the hypothesis that competitive interactions in polymicrobial biofilms drive adaptation of traditional pathogens—particularly Pseudomonas aeruginosa, the second most common organism isolated from chronic wound infections—resulting in phenotypes that facilitate infection persistence and treatment failure. Performance occurs in Blacksburg, Virginia, with a period of performance extending from August 19, 2026, through July 31, 2028. This is a Project Grant, an assistance type that funds developmental research in infectious disease at universities and research institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $199.1k | 8/19/26 |